These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35339752)

  • 41. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PCSK9: From discovery to therapeutic applications.
    Farnier M
    Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construction and application of a human scFv phage display library based on Cre‑LoxP recombination for anti‑PCSK9 antibody selection.
    Dong Y; Meng F; Wang Z; Yu T; Chen A; Xu S; Wang J; Yin M; Tang L; Hu C; Wang H; Cai J
    Int J Mol Med; 2021 Feb; 47(2):708-718. PubMed ID: 33416098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
    Elbitar S; Khoury PE; Ghaleb Y; Rabès JP; Varret M; Seidah NG; Boileau C; Abifadel M
    Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
    Cao Y; Yang H; Zhou X; Mao H; Gao T; Hu Z; He L; Pan F; Guo Z
    Biochem Biophys Res Commun; 2015 Aug; 463(4):712-8. PubMed ID: 26056005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
    Seidah NG
    Curr Opin Lipidol; 2016 Jun; 27(3):274-81. PubMed ID: 27031271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Sahebkar A
    Atherosclerosis; 2019 Apr; 283():69-78. PubMed ID: 30797988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
    McDonagh M; Peterson K; Holzhammer B; Fazio S
    J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective.
    Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A
    Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
    J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Schulz R; Schlüter KD; Laufs U
    Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.